The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer-related death. Its
mortality has increased in Western populations, with a minority of patients diagnosed at …

When Folkman first suggested a theory about the association between angiogenesis and
tumor growth in 1971, the hypothesis of targeting angiogenesis to treat cancer was formed …

Primary liver cancer is the sixth most common cancer overall and the second most common
cause of cancer mortality worldwide. Hepatocellular carcinoma accounts for up to 90% of all …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer.
Incidence of liver cancer varies geographically and parallels with the geographic prevalence …

Abstract Background: The anti-angiogenic Sorafenib is the only approved systemic therapy
for advanced hepatocellular carcinoma (HCC). However, acquired resistance limits its …

The third part of the European Federation of Societies for Ultrasound in Medicine and
Biology (EFSUMB) Guidelines on Interventional Ultrasound (INVUS) assesses the evidence …

Background: Angiogenesis inhibitors have become an important therapeutic approach in the
treatment of hepatocellular carcinoma (HCC) patients. The therapeutic inhibition of …

Hepatocellular carcinoma (HCC) is an aggressive tumor and the sixth most common form of
cancer worldwide. Surgery is the gold-standard treatment for local disease and often …